Fostamatinib is an effective second-line therapy in patients with immune thrombocytopenia.
Boccia R, Cooper N, Ghanima W, Boxer MA, Hill QA, Sholzberg M, Tarantino MD, Todd LK, Tong S, Bussel JB; FIT Clinical Trial Investigators.
Boccia R, et al. Among authors: boxer ma.
Br J Haematol. 2020 Sep;190(6):933-938. doi: 10.1111/bjh.16959. Epub 2020 Jul 23.
Br J Haematol. 2020.
PMID: 33439486
Free PMC article.
Clinical Trial.